Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK)

Price 1,368.00p on 03-12-2024 at 18:59:56
Change 26.50p 1.98%
Buy 1,370.50p
Sell 1,370.00p
Buy / Sell GSK Shares
Last Trade: Unknown 320,918.00 at 1,341.00p
Day's Volume: 7,976,877
Last Close: 1,368.00p
Open: 1,341.00p
ISIN: GB00BN7SWP63
Day's Range 1,341.00p - 1,372.00p
52wk Range: 1,282.50p - 1,820.00p
Market Capitalisation: £55,822m
VWAP: 1,359.2531p
Shares in Issue: 4,081m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 320,918 1,341.00p OTC Trade
00:00:00 - 03-Dec-24
Unknown* 5 1,370.00p OTC Trade
16:17:27 - 03-Dec-24
Unknown* 0 1,369.50p OTC Trade
15:55:03 - 03-Dec-24
Unknown* 5 1,368.50p OTC Trade
16:06:02 - 03-Dec-24
Unknown* 1 1,370.00p OTC Trade
15:52:45 - 03-Dec-24
Unknown* 16 1,368.50p OTC Trade
16:06:02 - 03-Dec-24
Unknown* 12 1,368.50p OTC Trade
16:06:02 - 03-Dec-24
Unknown* 1 1,369.00p OTC Trade
15:41:21 - 03-Dec-24
Sell* 5,996 1,368.00p SI Trade
Suspected SELL Trade
16:49:10 - 03-Dec-24
Unknown* 0 1,368.00p OTC Trade
15:45:12 - 03-Dec-24

Share Price History for Glaxosmithkline

Time period:
to
Date Open High Low Close Volume

Share News for Glaxosmithkline

LONDON BROKER RATINGS: Deutsche Bank raises AB Foods and Burberry

2nd Dec 2024 09:34

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More

TOP NEWS: GSK hails EU Approval of Menveo vaccine in new format

27th Nov 2024 09:23

(Alliance News) - GSK PLC on Wednesday said its meningitis vaccine, Menveo, has received approval from the European Commission in a new single-vial, fully liquid presentation. Read More

GSK's Blenrep combinations accepted for review by US FDA

25th Nov 2024 08:54

(Alliance News) - GSK PLC said on Monday that the US Food & Drug Administration accepted a biologics license application for its Blenrep combinations for the treatment of relapsed and refractory multiple myeloma, both forms of bone marrow cancer. Read More

TOP NEWS: GSK's Arexvy RSV vaccine approved in Japan for adults 50-59

22nd Nov 2024 08:40

(Alliance News) - GSK PLC said on Friday that Japan's Ministry of Health, Labour & Welfare has approved the expansion of its Arexvy respiratory syncytial virus vaccine to include adults aged 50 to 59 who are at increased risk of severe RSV. Read More

LONDON BRIEFING: GSK approval; Games Workshop trades ahead of forecast

22nd Nov 2024 07:52

(Alliance News) - London's FTSE 100 is called to open higher on Friday, while the pound and euro struggled ahead of a series key purchasing managers' index readings. Read More

FTSE 100 Latest
Value8,359.41
Change46.52

Login to your account

Forgot Password?

Not Registered